Skip to main content

ResearchHubLoading navigation…

Loading ResearchHub…

Haematologica | ResearchHub - ResearchHub

Explore the network

Research, people, journals and institutions — all in one place.

Explore

01Research 02Smart search 03Researchers 04Journals 05Institutions 06RHR Rankings 07ResearchHub platform 08Events

Work together

Turn ideas into projects, questions and reusable datasets.

Connect

01Projects 02Questions 03Datasets

Stay informed

Follow trends, opportunities and your research library.

Insights

01Research trends 02Opportunities 03Library 04Research services 05ResearchHub Pro 06Pricing

ResearchHub

Explore ResearchHub.

Personal

01Recommended research 02Research intelligence

Home Search Network Library Log in

ResearchHub

Research, connected

Explore the graph

ResearchGate

Download ResearchHub

GET IT ONGoogle PlayComing soonDownload on theApp StoreComing soonEXPLORE IT ONAppGalleryComing soon

Research

Research Researchers Journals Institutions RHR Rankings

Contribute

Projects Questions Datasets Opportunities

Platform

ResearchHub platform About Blog Community Help API Licensing

Shopping

Contact and support

Need help, have a question, or want to contact the ResearchHub team?

Contact and support support@aresearch.uk

© 2026 ResearchHub. Built for responsible scholarly connection.

Privacy Terms Cookies This work is licensed under Creative Commons Attribution 4.0 InternationalCC BY 4.0

Privacy-aware community infrastructure

Journal graph

Haematologica

Ferrata Storti Foundation (Haematologica) · ISSN 1592-8721

30

Verified works

0

Citations

—

Access

Researchers publishing here

0 linked researchers

Linked researcher profiles will appear as verified work is indexed.

Research in this journal

Response to Comment on: “Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia”2026 · Sarah Flossdorf · 0 citations

Philadelphia chromosome-like acute lymphoblastic leukemia: treat intensively, transplant selectively2026 · Lori Muffly · 0 citations

Salvage of primary graft failure with allogeneic hematopoietic stem cell transplantation from a deceased organ donor: report of a novel graft source2026 · Noa G. Holtzman, Matthew Muthiah, Maria Santamaria · 0 citations

CD25-based graft-versus-host disease prophylaxis after haploidentical hematopoietic stem cell transplantation: comparison of two prophylactic strategies2026 · Qianlin Liu, Hongru Chen, Xingyu Shao · 0 citations

Teclistamab desensitization of donor-specific antibodies in aplastic anemia2026 · Paulina García Maldonado, Valentine Jiménez Antolinez, Julia Colunga-Pedraza · 0 citations

The role of CHIP and pre-treatment neutropenia in patients treated with chimeric antigen receptor T cells for hematological malignancies2026 · Andreas Riedel, Alisha Weiß-Haug, Britta Merz · 0 citations

Allogeneic hematopoietic stem cell transplantation rather than specific front-line therapy is associated with long-term survival in blastic plasmacytoid dendritic cell neoplasm: the Mayo Clinic experience2026 · Naseema Gangat, Erica Andres, Clifford M. Csizmar · 0 citations

Measurable residual disease-negative remission of BRAF-V600Emutated acute myeloid leukemia with dabrafenib and trametinib2026 · Laura Polmann, Christoph Schliemann, Lisa M. Sgonina · 0 citations

Heterogeneity in access to clinical trials for innovative hemophilia treatments: a call for global equity2026 · Matteo Nicola Dario Di Minno, Kaan Kavakli, Angelika Batorova · 0 citations

Five-year results of short-course brentuximab vedotin combined with chemotherapy and radiation in early stage, unfavorable Hodgkin lymphoma2026 · Robert Stuver, Esther Drill, Laure Michaud · 0 citations

Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: “Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study”2026 · Tianxin Lyu · 0 citations

Response to Comment on: “Fibrinogen promotes acute myelogenous leukemia progression via miR-486/GPR153 axis”2026 · Liqing Zhu · 0 citations

Beyond venetoclax and azacitidine: CD70-targeted triplet therapy in acute myeloid leukemia2026 · 0 citations

BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax2026 · Alberto J. Arribas, Alex Zadro, Elisa Civanelli · 0 citations

Where would immune thrombocytopenia be without intravenous gammaglobulin?2026 · James B. Bussel, Jory M. Hirshman · 0 citations

Erratum to: “The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients”2026 · Shohei Mizuno, Luuk Gras, Laurien GA Baaij · 0 citations

Erratum to: “Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia”2026 · Salih Demir, Elena Boldrin, Stephanie Hampp · 0 citations

β-thalassemia as a progressive disease: age-related morbidity in the de-LIGHT study2026 · Khaled M. Musallam, Angela Vitrano, Alessandro Inzerillo · 0 citations

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience2026 · Cirino Botta, Andrea Rizzuto, Maria Speciale · 0 citations

Single-cell RNA editing identifies aggressive and favorable cellular states in chronic myelomonocytic leukemia2026 · Nisansala Wickramasinghe, Doan Bui, Surendra Neupane · 0 citations

Gilteritinib plus azacitidine in patients with newly diagnosed FLT3 mutation-positive acute myeloid leukemia who were ineligible for intensive chemotherapy: final results of the phase III LACEWING study2026 · Mark D. Minden, Hassan Sibai, Tomoki Naoe · 0 citations

Interleukin-17-associated inflammation in non-responders and B-cell remodeling after daratumumab in refractory immune thrombocytopenia2026 · Elsa Drivet, Galina Tsykunova, Ingrid M Egner · 0 citations

Independent prognostic value of semaphorin-4D, interleukin-1β and complement activation in newly diagnosed multiple myeloma patients2026 · Ioannis Ntanasis-Stathopoulos, Panagiota-Efstathia Nikolaou, Charalampos Filippatos · 0 citations

Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials2026 · Hugo Fernandez, Hillard Lazarus, Elisabeth Paietta · 0 citations

Real-world experience with IDH inhibitors in pediatric patients with IDH1- and IDH2-mutated acute myeloid leukemia and myelodysplastic syndrome2026 · Sara Zarnegar-Lumley, Lauren Pommert, Norman J. Lacayo · 0 citations

Exposure-response and dose simulation of belantamab mafodotin in combination with standards of care in patients with relapsed/refractory multiple myeloma2026 · Geraldine Ferron-Brady, Fernando Carreño, Theodoros Papathanasiou · 0 citations

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma2026 · Marie Christine Wesener, Uta Margareta Demel, Raphael Teipel · 0 citations

What a wonderful world: beyond relapsed pediatric acute myeloid leukemia2026 · Daisuke Tomizawa · 0 citations

Normal platelet function in a patient with ARHGEF1 deficiency2026 · Justine Suffit, Lionel Galicier, Theo Pigaglio · 0 citations

FLT3-directed therapy in acute myeloid leukemia: lessons from the final analysis of LACEWING2026 · Jennifer Marvin-Peek · 0 citations